Eye Injections for Diabetic Vision Loss: Two Treatment Comparison
Treatments studied
Part of Eyes & vision, Heart & circulation, Hormones & metabolism clinical trials.
This study compares two injectable medications (faricimab and biosimilar ranibizumab) used to treat diabetic retinopathy, a serious eye condition that can cause vision loss in people with diabetes. The trial will measure how well each medication works and track specific markers in your eye to understand treatment response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have diabetic retinopathy (diabetes-related damage to blood vessels in the eye), with or without swelling in the central vision area
- Your eye doctor believes you need an anti-VEGF injection (a type of medicine that reduces abnormal blood vessel growth)
- You have not received anti-VEGF or steroid injections in this eye within the past 5 months
- You have not had eye surgery or laser treatment in this eye within the past 3 months
- You can attend follow-up appointments and comply with study procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether one eye injection (aflibercept) works better than another (bevacizumab) for people with diabetic macular edema. Both are already used for this condition, and the goal is to see which provides better vision improvement.
This trial tests an eye injection called OLN324 for diabetic macular edema, a condition where fluid builds up in the retina and blurs vision. The treatment aims to improve vision and reduce swelling in the eye.
This study tests an experimental eye injection (OLN324) for people with diabetic macular edema, a condition where swelling in the back of the eye causes vision loss. The goal is to see if the injection can improve vision.
This trial tests a new eye-numbing gel against the standard numbing method to see which works better for patients getting regular anti-VEGF injections in the eye.
This study compares giving one versus multiple anti-VEGF injections (a medicine that reduces abnormal blood vessel growth) around the time of cataract surgery in people with diabetes. It aims to see which approach better protects the eye and improves outcomes.
This trial tests whether faricimab, an eye injection for certain eye conditions, affects kidney function in people with diabetes. It is for those with diabetic macular edema, wet age-related macular degeneration, or macular edema from a vein blockage, who are already taking kidney-protective medications.
Hear when a new Diabetic Retinopathy (DR) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.